EGFR and lung adenocarcinoma: Approximately 40% of Asian lung adenocarcinoma (LUAD) patients have driver gene mutations and could benefit from targeted therapies, such as tyrosine kinase inhibitors (TKIs) targeting sensitizing mutations in the epidermal growth factor receptor (EGFR) [1, 2].